ARCHIVES

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

This article is from The Cancer Letter archive.

Vol. 32 No. 21 | June 2, 2006

Download PDF Visit The Full Archive

Related Articles

FDA Oncology Division Director Says Goal to Make Review Process “Predictable”

August 2, 1996

Two Groups Take Different Approaches To Managing Toxicity Of Saltz Regimen.

June 22, 2001

Genetic Risk Factor Implicated In Prostate Cancer In Blacks

August 25, 2006

NIH Defines Misconduct

December 9, 1994

Varmus Wins ASCO’s Science Of Oncology Award; Sawyers To Give Karnofsky Lecture.

January 28, 2005

No Benefit To Shark Cartilage As Treatment, Large Trial Finds

July 27, 2007